ToxIVIG Study - Effect of Immunoglobulins on Mortality in Children with Toxic Shock Syndrome
- Conditions
- A40.0Sepsis due to streptococcus, group A
- Registration Number
- DRKS00034536
- Lead Sponsor
- Kinderklinik I, Universitätsmedizin Essen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 322
Inclusion Criteria
Timeframe: Admission between January 1, 2016, and December 31, 2023.
Age at admission = 28 days and < 18 years
Screening: ICD-10 codes A40.0, A41.0, A48.3, R57.2;
Inclusion: all cases with A48.3 + all other cases clinically meeting inclusion criteria for TSS
Exclusion Criteria
none
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the Effect of Intravenous Immunoglobulins on Mortality in Children with Toxic Shock Syndrome
- Secondary Outcome Measures
Name Time Method Evaluation of the effect of intravenous immunoglobulins in children with toxic shock syndrome on outcomes other than mortality.